Growth Metrics

Novavax (NVAX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to $34.2 million.

  • Novavax's Receivables - Net fell 6670.4% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 6670.4%. This contributed to the annual value of $116.0 million for FY2024, which is 6098.78% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Receivables - Net is $34.2 million, which was down 6670.4% from $226.4 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Receivables - Net registered a high of $478.2 million during Q1 2022, and its lowest value of $29.1 million during Q1 2024.
  • Over the past 5 years, Novavax's median Receivables - Net value was $111.6 million (recorded in 2022), while the average stood at $161.2 million.
  • As far as peak fluctuations go, Novavax's Receivables - Net soared by 74037.4% in 2022, and later crashed by 9011.84% in 2024.
  • Quarter analysis of 5 years shows Novavax's Receivables - Net stood at $455.0 million in 2021, then plummeted by 78.85% to $96.2 million in 2022, then soared by 216.93% to $304.9 million in 2023, then tumbled by 61.97% to $116.0 million in 2024, then crashed by 70.53% to $34.2 million in 2025.
  • Its Receivables - Net was $34.2 million in Q3 2025, compared to $226.4 million in Q2 2025 and $44.5 million in Q1 2025.